Choose ALUNBRIG® (brigatinib) Which Offers Efficacy in Previously Treated Patients

In a study of patients who had progressed on crizotinib, ALUNBRIG demonstrated clinically meaningful response rates and achieved meaningful median PFS for patients with and without brain metastases.1,2

Brigatinib (ALUNBRIG) is an NCCN Category 2A recommended treatment for patients post-crizotinib.3



A global, two-arm, open-label, multicenter trial in adult patients with locally advanced or metastatic ALK‑positive non-small cell lung cancer (NSCLC) who had progressed on crizotinib.1

ALTA consisted of 222 adult patients with locally advanced or metastatic ALK+ NSCLC that progressed on crizontinib.

Major efficacy outcome measure was confirmed overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as evaluated by an Independent Review Committee (IRC).1

Additional efficacy outcome measures included investigator-assessed ORR, duration of response (DOR), intracranial ORR, and intracranial DOR.

ALTA Patient Demographics

ALUNBRIG was studied in patients with locally advanced or metastatic ALK+ NSCLC.1

Patient characteristics in ALTA.

ALUNBRIG demonstrated clinically meaningful overall response rates (ORR) following crizotinib1

Results from 8-month median follow-up1

In 2-year median follow-upd—ALUNBRIG achieved meaningful PFS and OS after treatment with crizotinib2

Study Limitations: ALTA was not a controlled trial and was not prospectively designed for statistical comparisons between dosing arms.

In 8-month median follow-up—ALUNBRIG had clinically meaningful intracranial responses post-crizotinib1

Results from 8-month median follow-up1

Duration of intracranial response was measured from date of first intracranial response until intracranial disease progression (new lesions, intracranial target lesion diameter growth ≥20% from nadir, or unequivocal progression of nontarget lesions) or death.

In 2-year median follow-upd
ALUNBRIG achieved meaningful intracranial PFS post-crizotinib2

aThe median duration of follow-up was 8 months (range: 0.1-20.2).
bThe recommended dosing regimen is 90 mg orally once daily for the first 7 days; then increase the dose to 180 mg orally once daily.
c≥10 mm in longest diameter (at baseline).
dAdditional outcomes calculated as of September 29, 2017, 2 years after last enrollment (median follow-up of 19.6 months [range: 0.1-35.2] in the 90-mg arm and 24.3 months [range: 0.1-39.2] in the 90→180-mg arm).